Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

345
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
345
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

60
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
60
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

205
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
205
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

249
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
249
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

236
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
236

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Supporting the Implementation and Addressing the Challenges of the EU HTA Regulation.

Journal of market access & health policy·2026
Same author

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026
Same author

Ten years of European International Intensive Infectious Disease Courses (I3DC/IDEAL): long-term impact for undergraduate medical students.

BMC medical education·2026
Same author

Therapie·2026
Same author

How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?

Therapie·2026
Same author

Impact of Liquid Sublingual Immunotherapy on Health Care Resource Use in Allergic Rhinitis and Asthma in the Real-world EfficAPSI Study.

Journal of investigational allergology & clinical immunology·2025

Related Experiment Video

Updated: Mar 18, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Biosimilars: from Technical to Pharmacoeconomic Considerations.

Danièle Girault1, Jean-Hugues Trouvin2, Corinne Blachier-Poisson3

  • 1Laboratoire Novartis Pharma, Rueil Malmaison, France.

Therapie
|July 10, 2016
PubMed
Summary
This summary is machine-generated.

Biosimilars, similar biological medicines, offer economic benefits as patents expire. Recommendations focus on physician-patient communication and streamlined market entry for these complex drugs.

Keywords:
biosimilar pharmaceuticalshealth care costsrisk managementsubstitutiontraceability

More Related Videos

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.5K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K

Related Experiment Videos

Last Updated: Mar 18, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.5K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K

Area of Science:

  • Pharmacology
  • Biotechnology
  • Health Economics

Background:

  • Biosimilars are biological medicines highly similar to reference products, requiring rigorous comparative studies.
  • Unlike generics, biosimilars are complex and face specific regulatory requirements.
  • Expiring patents on high-cost biologicals in oncology, rheumatology, and gastroenterology present significant economic opportunities.

Purpose of the Study:

  • To outline recommendations for a successful biosimilar market launch in France.
  • To address the economic impact of biosimilars on the national health insurance system.
  • To define the roles of healthcare professionals and regulatory processes in biosimilar adoption.

Main Methods:

  • A round table discussion involving experts and stakeholders.
  • Analysis of the economic implications for the French healthcare system.
  • Formulation of recommendations for market integration and patient management.

Main Results:

  • Biosimilars are expected to have a considerable economic impact due to patent expirations.
  • Physicians play a crucial role in patient education and reassurance regarding biosimilars.
  • Efficient post-market surveillance and accelerated time-to-market are recommended.

Conclusions:

  • Successful biosimilar integration requires a multi-faceted approach.
  • Physician engagement and robust monitoring systems are key to patient safety and trust.
  • Streamlining regulatory pathways can expedite access to cost-effective biological therapies.